ImmuPharma (LON:IMM) Trading Up 27.3% - What's Next?

Key Points

• ImmuPharma's stock price surged 27.3% on Friday, reaching a last traded price of GBX 12.60 ($0.17) after closing at GBX 9.90 ($0.13).
• The company reported a net margin of 3,519.56% and a negative return on equity of 131.41%, with analysts predicting EPS of approximately -339.00 for the current year.
• ImmuPharma specializes in peptide-based therapeutics, focusing on treatments for autoimmune diseases, with its lead program being Lupuzor™ for Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price shot up 27.3% during trading on Friday . The stock traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). 4,543,810 shares were traded during mid-day trading, a decline of 46% from the average session volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Stock Performance

The firm has a market cap of £63.34 million, a PE ratio of -1,415.73 and a beta of 1.53. The firm's 50 day moving average price is GBX 7.92 and its two-hundred day moving average price is GBX 4.36.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.